Trial Profile
An Open-label, Multi-Center, Phase IIIb Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia Who Are Eligible for "7+3" or "5+2" Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Midostaurin (Primary) ; Cytarabine; Daunorubicin; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Registrational
- Sponsors Novartis; Novartis Pharma; Novartis Pharmaceuticals
- 20 Oct 2021 Status changed from active, no longer recruiting to completed.
- 29 Aug 2021 This trial has been completed in Italy (End Date 09 July 2021), according to European Clinical Trials Database record.
- 29 Jul 2021 This trial has been completed in Finland (End Date 09 July 2021), according to European Clinical Trials Database record.